tiprankstipranks
Trending News
More News >
Apiam Animal Health Ltd. (AU:AHX)
ASX:AHX
Australian Market

Apiam Animal Health Ltd. (AHX) AI Stock Analysis

Compare
5 Followers

Top Page

AU

Apiam Animal Health Ltd.

(Sydney:AHX)

Rating:64Neutral
Price Target:
AU$0.50
▲(25.00%Upside)
Apiam Animal Health Ltd. benefits from strong financial performance and cash flow management, providing a solid base for future growth. However, the high P/E ratio suggests overvaluation, and technical indicators show weak momentum, which tempers the overall stock score.

Apiam Animal Health Ltd. (AHX) vs. iShares MSCI Australia ETF (EWA)

Apiam Animal Health Ltd. Business Overview & Revenue Model

Company DescriptionApiam Animal Health Limited, a vertically integrated animal health company, provides veterinary products and services to production and companion animals in Australia. The company operates through three segments: Dairy and Mixed, Feedlots, and Pigs. It engages in the provision of veterinary wholesale, diagnostics laboratories, custom vaccines, logistics, and other ancillary services. The company offers companion animal, dairy, swine and poultry, beef feedlot, equine, sheep, and genetic services. It also provides telemedicine, remote video headgear, health management apps for production animals systems, benchmarking databases, and herd management software. The company offers general animal health products through eCommerce. It provides its services through animal veterinary clinics. The company was founded in 1998 and is based in Bendigo, Australia.
How the Company Makes MoneyApiam Animal Health Ltd. generates revenue through its diversified veterinary services and product offerings. The primary revenue streams include veterinary consultation fees, sales of pharmaceuticals and health products, and laboratory services. The company benefits from its extensive network of veterinary clinics and a strong presence in the rural and regional markets. Additionally, strategic partnerships with pharmaceutical companies and expansion through acquisitions contribute significantly to its earnings, enhancing its market reach and service capabilities.

Apiam Animal Health Ltd. Financial Statement Overview

Summary
Apiam Animal Health Ltd. demonstrates strong financial performance with notable revenue growth and improving operational efficiencies. While profitability margins have room for improvement, robust cash flow management and balanced debt levels provide a solid foundation for future growth.
Income Statement
75
Positive
Apiam Animal Health Ltd. has shown a strong revenue growth trajectory with a significant increase from previous years, indicating robust business expansion. The Gross Profit Margin has improved substantially, reflecting effective cost management. However, the Net Profit Margin remains relatively low, suggesting room for improvement in overall profitability. The EBIT and EBITDA margins have shown positive trends, enhancing operational efficiency.
Balance Sheet
70
Positive
The company maintains a moderate Debt-to-Equity Ratio, indicating a balanced approach to leveraging. Return on Equity (ROE) reflects a moderate level of profitability relative to shareholder investments. The Equity Ratio is stable, suggesting a sound capital structure. However, the total debt level has increased, which could pose future financial risks if not managed properly.
Cash Flow
80
Positive
Apiam Animal Health Ltd. demonstrates a healthy Cash Flow position with consistent Free Cash Flow generation and positive Operating Cash Flow growth. The Free Cash Flow to Net Income ratio indicates efficient cash management, supporting potential reinvestment opportunities. The Operating Cash Flow to Net Income Ratio signifies strong cash generation capabilities from core operations.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
206.45M204.66M191.76M157.06M126.18M118.33M
Gross Profit
47.31M137.16M28.81M25.98M20.57M19.26M
EBIT
47.11M12.36M6.89M7.95M8.21M7.66M
EBITDA
19.56M23.52M17.11M16.31M14.64M13.72M
Net Income Common Stockholders
127.00K4.93M2.28M4.64M5.08M4.17M
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.45M1.76M3.17M2.85M2.15M2.51M
Total Assets
140.25M255.78M246.04M199.18M157.28M141.67M
Total Debt
51.63M101.78M98.03M63.39M55.04M51.10M
Net Debt
49.18M100.02M94.86M60.55M52.89M48.59M
Total Liabilities
73.64M133.75M128.14M90.49M76.46M73.23M
Stockholders Equity
65.74M122.02M117.87M108.55M79.81M67.41M
Cash FlowFree Cash Flow
13.31M14.01M9.25M10.21M8.71M5.52M
Operating Cash Flow
19.18M18.88M17.45M15.08M13.69M7.51M
Investing Cash Flow
-6.17M-10.91M-40.62M-32.49M-16.56M-14.86M
Financing Cash Flow
-12.42M-9.39M23.49M18.11M2.51M7.99M

Apiam Animal Health Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.40
Price Trends
50DMA
0.40
Positive
100DMA
0.39
Positive
200DMA
0.41
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
51.13
Neutral
STOCH
19.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHX, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.40, and below the 200-day MA of 0.41, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.13 is Neutral, neither overbought nor oversold. The STOCH value of 19.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:AHX.

Apiam Animal Health Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUAHX
64
Neutral
AU$74.50M506.250.11%4.94%2.00%-94.63%
62
Neutral
$6.84B11.412.80%3.87%2.70%-24.58%
$76.28B26.6715.38%1.85%
$1.46B-21.31%
$5.63B1,072.730.52%2.23%
AUSHL
72
Outperform
AU$12.68B23.176.86%4.05%10.15%6.20%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:AHX
Apiam Animal Health Ltd.
0.40
0.07
21.21%
CMXHF
CSL
159.14
-23.30
-12.77%
MEOBF
Mesoblast Limited
1.44
0.73
102.82%
RMSYF
Ramsay Health Care
23.67
-7.77
-24.71%
AU:SHL
Sonic Healthcare Limited
26.64
2.74
11.46%

Apiam Animal Health Ltd. Corporate Events

Apiam Animal Health Announces Leadership Transition with Interim CEO Appointment
Jun 5, 2025

Apiam Animal Health Limited has announced a leadership transition with the departure of Dr. Chris Richards as CEO and Managing Director after over nine years. Bruce Dixon, a non-executive director with a proven track record in profitable growth, will serve as Interim Managing Director while the company searches for a new CEO. The transition aims to maintain focus on revenue opportunities and operational efficiencies within Apiam’s clinic portfolio, signaling a strategic shift in leadership to support continued growth and development.

The most recent analyst rating on (AU:AHX) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Apiam Animal Health Ltd. stock, see the AU:AHX Stock Forecast page.

Apiam Animal Health Reports Resilient FY25 Results and Launches AI Tool
May 5, 2025

Apiam Animal Health Ltd. reported resilient financial results for the fiscal year 2025 to date, despite challenges in the equine market and reduced export diagnostic testing revenues. The company has divested two underperforming clinics to improve EBIT and is rolling out CoVet, an AI-driven clinical tool, to enhance efficiency and customer experience across its network. This strategic move is expected to streamline workflows, increase clinic capacity, and improve both employee and customer satisfaction, positioning Apiam favorably in the veterinary services industry.

Apiam Animal Health Issues Performance Rights in Employee Incentive Scheme
Apr 1, 2025

Apiam Animal Health Ltd. announced the issuance of 128,671 performance rights as part of an employee incentive scheme. These securities are unquoted and are not intended to be listed on the ASX, reflecting the company’s strategy to reward and retain its workforce, potentially impacting its operational efficiency and stakeholder engagement.

Apiam Animal Health Ltd. Announces Quotation of New Securities
Mar 27, 2025

Apiam Animal Health Ltd. announced the application for the quotation of 1,420,737 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a dividend or distribution plan, potentially impacting the company’s financial structure and providing additional liquidity options for stakeholders.

Apiam Animal Health Director Increases Shareholding
Mar 25, 2025

Apiam Animal Health Ltd. announced a change in the director’s interest, with Christopher Richards acquiring 112,406 fully paid ordinary shares, bringing his total to 43,386,270 shares. This acquisition, conducted through a market purchase, reflects a strategic move that could potentially impact the company’s market positioning and stakeholder confidence.

Apiam Animal Health Updates Dividend Reinvestment Plan Details
Mar 19, 2025

Apiam Animal Health Ltd. has announced an update regarding the issue price of shares for shareholders participating in the Dividend Reinvestment Plan for the H1 FY2025 Interim Dividend. This update clarifies the financial arrangements for shareholders, potentially impacting their investment decisions and reflecting the company’s ongoing commitment to shareholder value.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.